Multinational | Europeb | Mediterraneanb | Asiab | Middle Eastb | Central & South Americab | USA/Canadab | Ungroupedb | |
---|---|---|---|---|---|---|---|---|
Sources [ref] |
Additional file 1: Table S1 [S1-S4] |
Additional file 1: Table S2 [S5-S37] |
Additional file 1: Table S3 [S38-S57] |
Additional file 1: Table S4 [S58-S64] |
Additional file 1: Table S4 [S65-S73] |
Additional file 1: Table S5 [S74-S81] |
Additional file 1: Table S5 [S82-S96] |
Additional file 1: Table S6 [S97-S100] |
Number of groups | 13 | 35 | 20 | 7 | 11 | 9 | 18 | 4 |
MV for >48 h for <75 %c | 0 | 1 | 1 | 1 | 0 | 1 | 2 | 0 |
Trauma ICUsd | 1 | 2 | 6 | 0 | 4 | 0 | 6 | 0 |
Bronchoscopic samplinge | 3 | 18 | 13 | 1 | 1 | 1 | 7 | 1 |
Intervention period | 1 | 2 | 0 | 0 | 1 | 1 | 1 | 0 |
Study publication year (range) | 1993-2012 | 1988-2016 | 1987-2012 | 2001-2016 | 2000-2013 | 1995-2013 | 1987-2014 | 1987-2015 |
Numbers of patients per study group; median (IQR) |
2082; 1029-3413 |
385; 145-764 |
194; 101-318 |
952; 301-16426 |
260; 100-724 |
270; 233-427 |
340; 277-678 |
174; 65-331 |
Duration of MV (days); median (IQR) | 6; 5-7 | 11; 7.4-14 | 8; 6.5-10.2 | 7.5; 6-9 | 8.9; 7.1-10 | 9.6; 7.6-10 | 5.5; 4–10.5 | 9.2; 4–10.6 |
VAP incidence; | ||||||||
• per 1000 ventilator days; o mean; f o 95 % CI |
30 · 6; 20 · 4–40 · 7 |
24 · 3; 18 · 1–30 · 4 |
29.8 % 21 · 4–38 · 2 |
29 · 7; 15.9–43 · 5 |
34 · 0; 22.9–44 · 9 |
31 · 5; 19 · 3–43 · 6 |
26 · 7; 17 · 9–35 · 5 |
33 · 7; 15 · 4–51 · 9 |
Acinetobacter (all) VAP incidenceg | ||||||||
• per 1000 ventilator days; o mean; h o 95 % CI |
4 · 2; 2 · 8–6 · 2 |
1 · 3; 0.7–2 · 5 |
3 · 5; 2.0–6 · 1 |
5.5; 2 · 4–12 · 8 |
8.8; 6 · 2–12 · 7 |
3 · 3; 1 · 8–6 · 2 |
1 · 2; 0 · 8–2 · 1 |
3 · 1; 1 · 9–5 · 2 |
Acinetobacter baumanii VAP incidence i | ||||||||
• per 1000 ventilator days; o mean; j o 95 % CI |
8 · 2; 0 · 7–3 · 5 |
0 · 51; 0.1–0 · 9 |
2 · 8; 1 · 4–5 · 4 |
6.6; 2 · 1–20 · 1 |
18.0; 9 · 8–33 · 1 |
4 · 4; 2 · 0–10 · 0 |
1 · 2; 0 · 6–2 · 6 |